

# Veena Venugopalan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6904892/publications.pdf>

Version: 2024-02-01

27  
papers

305  
citations

1040056

9  
h-index

888059

17  
g-index

27  
all docs

27  
docs citations

27  
times ranked

419  
citing authors

#	ARTICLE	IF	CITATIONS
1	Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0161121.	3.2	4
2	Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI). <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2022, 2, .	0.5	5
3	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	3.2	9
4	Implementation of a $\beta$ -lactam therapeutic drug monitoring program: Experience from a large academic medical center. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1586-1591.	1.0	9
5	Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 152-158.	1.0	1
6	Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110002.	1.0	0
7	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab371.	0.9	36
8	Early therapeutic monitoring of $\beta$ -lactams and associated therapy outcomes in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3644-3651.	3.0	44
9	An Update on Existing and Emerging Data for Meropenem-Vaborbactam. <i>Clinical Therapeutics</i> , 2020, 42, 692-702.	2.5	17
10	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa051.	0.9	36
11	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	25
12	1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing <i>Enterobacterales</i> BloodStream Infections (REDUCE-BSI). <i>Open Forum Infectious Diseases</i> , 2020, 7, S786-S787.	0.9	0
13	143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption. <i>Open Forum Infectious Diseases</i> , 2020, 7, S201-S202.	0.9	0
14	1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S786-S786.	0.9	0
15	Clinical and Microbiologic Outcomes in Patients with Monomicrobial <i>Stenotrophomonas maltophilia</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	28
16	Use of an Anti-Infective Medication Review Process at Hospital Discharge to Identify Medication Errors and Optimize Therapy. <i>Journal of Pharmacy Practice</i> , 2019, 32, 488-492.	1.0	3
17	2425. Clinical and Microbiologic Outcomes Among Patients With Monomicrobial <i>Stenotrophomonas maltophilia</i> Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S725-S725.	0.9	0
18	Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. <i>Microbiology Insights</i> , 2018, 11, 117863611880454.	2.0	7

#	ARTICLE	IF	CITATIONS
19	SCAN: A novel approach for vancomycin time-out. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1501-1503.	1.8	4
20	Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 719-723.	2.5	13
21	Preparing Students to Enter the Race for Postgraduate Training. <i>Journal of Pharmacy Practice</i> , 2017, 30, 476-482.	1.0	10
22	Impact of an antimicrobial stewardship initiative on time to administration of empirical antibiotic therapy in hospitalized patients with bacteremia. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 511-519.	1.0	9
23	Impact of an Extended Infusion $\beta$ -lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections. <i>Open Forum Infectious Diseases</i> , 2017, 4, S299-S299.	0.9	0
24	Administration of a survey to evaluate the attitudes of house staff physicians towards antimicrobial resistance and the antimicrobial stewardship programme at a community teaching hospital. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 4, 21-27.	2.2	25
25	Management of skin and soft-tissue infections at a community teaching hospital using a severity-of-illness tool. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3268-3275.	3.0	12
26	Incidence of Antiretroviral Drug Interactions During Hospital Course. <i>Journal of Pharmacy Technology</i> , 2014, 30, 48-53.	1.0	7
27	Impact of Gastric Acidity on the Acquisition of Cholera Post Gastric Bypass. <i>Bariatric Surgical Patient Care</i> , 2013, 8, 113-116.	0.5	1